Talniflumate structure
|
Common Name | Talniflumate | ||
---|---|---|---|---|
CAS Number | 66898-62-2 | Molecular Weight | 414.334 | |
Density | 1.5±0.1 g/cm3 | Boiling Point | 534.6±50.0 °C at 760 mmHg | |
Molecular Formula | C21H13F3N2O4 | Melting Point | 165-167ºC | |
MSDS | N/A | Flash Point | 277.1±30.1 °C |
Use of TalniflumateTalniflumate (BA 7602-06) is the prodrug of Niflumic acid (HY-B0493), exerting its activity in the body through conversion to niflumic acid by esterase[1]. Talniflumate is an orally active ca2+-activated Cl- channel (CaCC) blocker. Talniflumate can be used as an analgesic and anti-inflammatory agent in cystic fibrosis mouse model of distal intestinal obstructive syndrome[2]. |
Name | (3-oxo-1H-2-benzofuran-1-yl) 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate |
---|---|
Synonym | More Synonyms |
Description | Talniflumate (BA 7602-06) is the prodrug of Niflumic acid (HY-B0493), exerting its activity in the body through conversion to niflumic acid by esterase[1]. Talniflumate is an orally active ca2+-activated Cl- channel (CaCC) blocker. Talniflumate can be used as an analgesic and anti-inflammatory agent in cystic fibrosis mouse model of distal intestinal obstructive syndrome[2]. |
---|---|
Related Catalog | |
Target |
IC50: ca2+-activated Cl- channel (CaCC)[1] |
In Vivo | Talniflumate (oral chow; 0.4 mg/g; 21 days) significantly increases CF mouse survival from 26 to 77%. It does not alter crypt goblet cell numbers or change intestinal expression of mCLCA3 but tends to decrease crypt mucoid impaction[1]. Animal Model: CF mice with distal intestinal obstructive syndrome (DIOS)[1] Dosage: 0.4 mg/g Administration: Oral chow; 21 days Result: Increased survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome. |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 534.6±50.0 °C at 760 mmHg |
Melting Point | 165-167ºC |
Molecular Formula | C21H13F3N2O4 |
Molecular Weight | 414.334 |
Flash Point | 277.1±30.1 °C |
Exact Mass | 414.082733 |
PSA | 77.52000 |
LogP | 5.59 |
Vapour Pressure | 0.0±1.4 mmHg at 25°C |
Index of Refraction | 1.625 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
HS Code | 2934999090 |
---|
~78% Talniflumate CAS#:66898-62-2 |
Literature: Los, M.; Boned, J. E.; Piccinali, C. Farmaco. Prat., 1981 , vol. 36, # 5 p. 372 - 385 |
~51% Talniflumate CAS#:66898-62-2 |
Literature: Los, M.; Boned, J. E.; Piccinali, C. Farmaco. Prat., 1981 , vol. 36, # 5 p. 372 - 385 |
~% Talniflumate CAS#:66898-62-2 |
Literature: Farmaco. Prat., , vol. 36, # 5 p. 372 - 385 |
~% Talniflumate CAS#:66898-62-2 |
Literature: Farmaco. Prat., , vol. 36, # 5 p. 372 - 385 |
HS Code | 2934999090 |
---|---|
Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
3-oxo-1,3-dihydro-2-benzofuran-1-yl 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylate |
Talniflumate |
2-[[3-(Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid 1,3-Dihydro-3-oxo-1-isobenzofuranyl Ester |
Phthalidyl 2-(a,a,a-Trifluoro-m-toluidino)nicotinate |
3-Pyridinecarboxylic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-, 1,3-dihydro-3-oxo-1-isobenzofuranyl ester |
Lomucin |
Somalgen |
Purotoxin 1 |
BA 7602-06 |
3-Oxo-1,3-dihydro-2-benzofuran-1-yl 2-{[3-(trifluoromethyl)phenyl]amino}nicotinate |